Stockreport
Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases [Yahoo! Finance]
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
Study designed to support potential label expansion into additional settings of cholestatic pruritus Topline data expected in Q4 2026 FOSTER CITY, Calif., March 16, 2026 BUSINESS WIRE )--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced completion of enrollment in EXPAND, a Phase 3 randomized, double-blind, placebo-controlled study evaluating LIVMARLI ® (maralixibat) for the treatment of cholestatic pruritus in patients aged 6 months or older with rare cholestatic liver diseases, including biliary atresia. Cholestatic liver diseases are characterized by impaired bile flow, resulting in elevated serum bile acids, severe pruritus, and significantly reduced quality of life. While LIVMARLI is approved in the United States and European Union for the treatment of cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC), patients with other rare cholestatic liver diseases continue to exper
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | MIRM | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
MIRM alerts
MIRM alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
NEWS
NEWS
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)[Business Wire]
- ClearBridge SMID Cap Growth strategy initiates new positions, exits several in Q1 [Seeking Alpha][Seeking Alpha]
- A Look At Mirum Pharmaceuticals (MIRM) Valuation After Strong Long Term Share Performance [Yahoo! Finance][Yahoo! Finance]
- Mirum Pharmaceuticals (MIRM) had its price target raised by TD Cowen from $117.00 to $125.00. They now have a "buy" rating on the stock.[MarketBeat]
- Mirum Pharmaceuticals (MIRM) had its "buy" rating reaffirmed by HC Wainwright. They now have a $130.00 price target on the stock.[MarketBeat]
- More
MIRM
SEC Filings
SEC Filings
- 4/16/26 - Form 4
- 4/15/26 - Form 144
- 4/8/26 - Form 8-K/A
- MIRM's page on the SEC website
- More